论文部分内容阅读
目的探讨艾易舒与替加氟联合治疗晚期消化道肿瘤的临床疗效。方法收集许昌市中心医院2012年1月至2014年6月收治的晚期消化道肿瘤患者中,选择具有可比性的100例作为研究对象,并将其随机分成观察组与对照组,两组消化道肿瘤患者均给予常规手术与化疗治疗,对照组患者在此基础上给予替加氟治疗,而观察组患者在此基础上给予替加氟与艾易舒的联合治疗,治疗结束后对比两组患者的临床疗效以及不良反应的发生情况。结果观察组消化道肿瘤患者的有效率为86%,明显高于对照组(66%),二组比较差异有统计学意义(P<0.05)。观察组消化道肿瘤患者的不良反应发生率明显高于对照组,二组比较差异有统计学意义(P<0.05)。结论艾易舒与替加氟联合方案治疗晚期消化道肿瘤的临床疗效好,能有效降低患者在化疗期间的不良反应,值得临床的推广及应用。
Objective To investigate the clinical efficacy of Yi Yi Shu combined with tegafur in the treatment of advanced gastrointestinal tumors. Methods From January 2012 to June 2014, patients with advanced gastrointestinal cancer admitted to Central Hospital of Xuchang from January 2012 to June 2014 were selected and compared with 100 patients who were comparable to the observation group and the control group. Two groups of digestive tract Tumor patients were given conventional surgery and chemotherapy, patients in the control group were given tegafur on the basis of treatment, while patients in the observation group were given tegafur and Yi Yi Shu combination therapy, after the end of treatment compared two groups of patients The clinical efficacy and incidence of adverse reactions. Results The effective rate of the patients in the observation group was 86%, which was significantly higher than that of the control group (66%). The difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in patients with gastrointestinal cancer in the observation group was significantly higher than that in the control group, with significant difference between the two groups (P <0.05). Conclusion Ai Yi Shu and tegafur combination regimen for the treatment of advanced gastrointestinal tumors with good clinical efficacy, can effectively reduce the adverse reactions in patients during chemotherapy, it is worth the clinical promotion and application.